BioPharmSignal logoBioPharmSignal

Biotech News

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Context Therapeutics (CNTX)Context TherapeuticsCompany update

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company’s CT-95 and

Related news

CNTXContext Therapeutics2026-08-05 20:15 EST

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

CNTXContext Therapeutics2026-07-06 20:07 EST

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

CGEMCullinan Therapeutics, Inc.2026-06-10 11:30 EST

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

BNTXBioNTech2026-08-20 09:30 EST

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

View all latest news

Context Therapeutics

Solid-Tumor T-Cell Engagers Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors. CTIM-76 CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen. CT-95 CT-95 is a...

Recent company news

CNTXContext Therapeutics2026-08-05 20:15 EST

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

CNTXContext Therapeutics2026-07-10 20:05 EST

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CNTXContext Therapeutics2026-07-06 20:07 EST

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

CNTXContext Therapeutics2026-06-15 10:30 EST

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

CNTXContext Therapeutics2026-06-09 20:10 EST

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
0.50 USD
Market cap
222.35M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States